Avenue Therapeutics (ATXI) Announces New Drug Application for IV Tramadol Accepted for Review by...
IV tramadol for the management of moderate to moderately severe pain in adults in a medically supervised health care setting.
Fortress Bio (FBIO) Inches Closer to $3.00 on Major News.
Fortress Bio (FBIO) Inches Closer to $3.00 on Major News.
Citius Pharma (CTXR) Inches Closer to the Next Phase...
Video: How Superbugs Get Started.
A World Health Organization (WHO) report released April 2014 stated, "this serious threat is no longer a prediction for the future, it is happening...
Citius (CTXR) Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial
PHASE III PROGRESS
October 7th, 2019, Citius Completes 40% - Triggers Data Being Analyzed (is it working?).December 19th, 2019...
Okay, so What’s Next for Citius Pharma (CTXR) $1.16?
Dawson James Broker/Dealer Updates. Price Target Remains at $7.00.
"OK, So what’s Next? Topline data from the superior efficacy...
Citius Pharma (CTXR) $1.20. Price Target Upped to $4.00 at HC Wainright.
STREET INSIDER
H.C. Wainwright analyst Vernon Bernardino raised the price target on Citius Pharmaceuticals...
VIDEO: Dyadic (DYAI) CEO Explains What his Industry is Doing to Defeat Coronavirus (FoxNews).
Jan. 27, 2020 - 5:24 - Dyadic International CEO Mark Emalfarb discusses what’s being done to stop...
Could Dyadic (DYAI) $5.75 Provide a Solution to Help Mass Produce Vaccines to Battle...
Dyadic (DYAI) has developed a biomanufacturing technology platform, nicknamed C1 which helps to speed the development, lower the manufacturing cost and potentially...
CoronaVirus Watch List Stocks in the News (Bloomberg, Benzinga).
INITIAL WATCHLIST: CoronaVirus Watch List | Superbug Stock Review
Aethlon Medical, Inc. (NASDAQ: AEMD) $2.40 Alpha Pro Tech, Ltd. (NYSE: APT)...
Biotech 5 Pack. 5 Biotech Stocks We Expect to Double in 2020.
Our First Newsletter of 2020, We Come out Swinging!
Yes, you read it right. Five of our favorite...